BrendaWCooperMD

Oncology • Cleveland, OH

Hematologic Oncology

Professor of Medicine, Case West Res University

Join to view full profile

Dr. Cooper is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cooper's full profile

Already have an account?

Office
11100 Euclid Ave
Cleveland, OH 44106
Phone+1 216-844-8500

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1987 - 1989
Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 1984 - 1987
Johns Hopkins University School of MedicineClass of 1984

Certifications & Licensure

OH State Medical License 1989 - 2025
MD State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia Start of enrollment: 1994 Aug 01
Completed
Phase 1
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 2
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer Start of enrollment: 1999 Feb 01
Completed
Phase 2
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome Start of enrollment: 1998 Sep 01
Completed
Phase 1
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes Start of enrollment: 2000 Jul 01
Completed
Phase 2
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS Start of enrollment: 2002 Sep 01
Completed
Phase 2
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia Start of enrollment: 2009 Jul 01
Completed
Phase 1, Phase 2
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2007 Sep 01
Completed
Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2011 Sep 16
Active, not recruiting
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Oct 08
Completed
Phase 1
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Active, not recruiting
Phase 2
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

12 citations
Aggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models.
Gouri Dharmavaram, Shufen Cao, Suchitra Sundaram, Sabarish Ayyappan, Kirsten M Boughan
American Journal of Hematology. 2020-04-20
8 citations
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma
Ehsan Malek, Vinita Gupta, Richard J. Creger, Paolo Caimi, Anant Vatsayan
Leukemia & Lymphoma. 2018-01-02
34 citations
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Molly Gallogly, Hillard M. Lazarus, Brenda W. Cooper
Therapeutic Advances in Hematology. 2017-08-19

Abstracts/Posters

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-_ S...
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Grant Support

SB-715992 In Acute LeukemiasNational Center For Research Resources2005–2006
Mechanism Based Phase I Trial Of Topotecan In LeukemiaNational Cancer Institute1999–2000
Sequential Topotecan &Etoposide For Patients With Myeloid LeukemiaNational Center For Research Resources1997–1999

Professional Memberships

American Society of Clinical Oncology - ASCO
Member